Valuation: Autolus Therapeutics plc

Market Cap 610M 523M 488M 448M 842M 58.26B 856M 5.76B 2.26B 29.22B 2.29B 2.24B 96.61B P/E 2026 *
-2.97x
P/E 2027 * -3.39x
Enterprise Value 553M 474M 443M 406M 764M 52.81B 776M 5.22B 2.04B 26.49B 2.07B 2.03B 87.57B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.53x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+6.77%
1 week+15.14%
Current month+63.82%
1 month+74.35%
3 months+49.75%
6 months+48.84%
Current year+22.66%
1 week 2.04
Extreme 2.04
2.54
1 month 1.38
Extreme 1.38
2.54
Current year 1.18
Extreme 1.175
2.54
1 year 1.18
Extreme 1.175
2.54
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Director

310,000 0.1866%
18/3/26 Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
+6.99%+15.14%+36.36%-24.43% 610M
+3.55%+5.00%+46.54%-0.77% 80.91B
+5.49%+20.35%-38.64%-38.47% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-1.80%+13.14%+167.24% 47.97B
+2.67%+4.70%+57.48%-17.50% 31.41B
+144.88%+149.22%+468.54%+42.85% 25.14B
+3.20%+5.76%+49.46%+96.87% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+4.68%+66.64%+126.90% 16.93B
Average +17.68%+2.64%+69.36%+59.53% 35.32B
Weighted average by Cap. +13.24%+3.06%+51.25%+48.29%

Financials

2026 *2027 *
Net sales 150M 128M 120M 110M 207M 14.32B 210M 1.42B 554M 7.18B 562M 550M 23.74B 192M 165M 154M 141M 266M 18.39B 270M 1.82B 712M 9.22B 722M 707M 30.5B
Net income -212M -182M -170M -156M -293M -20.29B -298M -2.01B -786M -10.18B -797M -780M -33.65B -184M -158M -147M -135M -254M -17.56B -258M -1.74B -680M -8.81B -690M -675M -29.12B
Net Debt -57M -48.89M -45.66M -41.89M -78.77M -5.45B -80.07M -539M -211M -2.73B -214M -209M -9.03B 69.6M 59.7M 55.75M 51.15M 96.18M 6.65B 97.77M 658M 258M 3.34B 261M 256M 11.03B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
20/08/26 US$2.441 +6.59% 4,277,748
18/08/26 US$2.290 +0.44% 3,363,410
17/08/26 US$2.280 +6.05% 3,036,041
14/08/26 US$2.150 -3.15% 2,395,470
13/08/26 US$2.220 +4.72% 2,242,456
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.290USD
Average target price
8.725USD
Spread / Average Target
+281.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock